The reported multivariate analysis suggests that SNP (XRCC1 or wt XRCC3 Thr241Met and XRCC1 or GSTA1) and dosimetric data (mean dose to whole breast) may be successfully used to predict acute toxicity in BC patients undergoing RT with/without adjuvant chemotherapy. This evidence concerns the gene XRCC3 and breast cancer.